Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sham Mailankody

Showing results (111-120 of 174) with videos related to

Pageof 18
Sort By:
Blood Cancer Journal|October 13, 2025
Correction: Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myelomaTara Sebastian, Sridevi Rajeeve, Tasmin Farzana, et al.
Leukemia|February 5, 2025
Phase 1 clinical trial of B-Cell Maturation Antigen (BCMA) NEX-T® Chimeric Antigen Receptor (CAR) T cell therapy CC-98633/BMS-986354 in participants with triple-class exposed multiple myelomaGayathri Ravi, Shambavi Richard, Shaji Kumar, et al.
JAMA Oncology|July 19, 2019
Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple MyelomaOla Landgren, Jonathan N Hofmann, Charlene M McShane, et al.
Blood Cancer Journal|July 25, 2023
Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myelomaCarlyn Rose Tan, Andriy Derkach, David Nemirovsky, et al.
Blood Advances|September 29, 2023
Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groupsUrvi A Shah, Erin Moshier, Andriy Derkach, et al.
Blood Cancer Journal|May 1, 2026
A differentiated effector T cell repertoire defines a functionally high-risk group of smoldering myeloma patientsRoss S Firestone, Anish K Simhal, Theresia Akhlaghi, et al.
Leukemia & Lymphoma|October 25, 2022
A short course of daratumumab in patients with multiple myeloma and minimal residual disease after induction therapyKarthik Nath, Tala Shekarkhand, Meghan Salcedo, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 23, 2020
Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple MyelomaSusan Bal, Heather J Landau, Gunjan L Shah, et al.
Research Square|February 26, 2024
Comparison of Infectious Complications with BCMA-directed Therapies in Multiple MyelomaAlexander Lesokhin, Karthik Nath, Tala Shekarkhand, et al.
Leukemia & Lymphoma|December 23, 2015
Bone marrow abnormalities and early bone lesions in multiple myeloma and its precursor disease: a prospective study using functional and morphologic imagingManisha Bhutani, Baris Turkbey, Esther Tan, et al.
Pageof 18

Showing results (111-120 of 174) with videos related to

Sort By:
Pageof 18
Blood Cancer Journal|October 13, 2025
Correction: Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myelomaTara Sebastian, Sridevi Rajeeve, Tasmin Farzana, et al.
Leukemia|February 5, 2025
Phase 1 clinical trial of B-Cell Maturation Antigen (BCMA) NEX-T® Chimeric Antigen Receptor (CAR) T cell therapy CC-98633/BMS-986354 in participants with triple-class exposed multiple myelomaGayathri Ravi, Shambavi Richard, Shaji Kumar, et al.
JAMA Oncology|July 19, 2019
Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple MyelomaOla Landgren, Jonathan N Hofmann, Charlene M McShane, et al.
Blood Cancer Journal|July 25, 2023
Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myelomaCarlyn Rose Tan, Andriy Derkach, David Nemirovsky, et al.
Blood Advances|September 29, 2023
Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groupsUrvi A Shah, Erin Moshier, Andriy Derkach, et al.
Blood Cancer Journal|May 1, 2026
A differentiated effector T cell repertoire defines a functionally high-risk group of smoldering myeloma patientsRoss S Firestone, Anish K Simhal, Theresia Akhlaghi, et al.
Leukemia & Lymphoma|October 25, 2022
A short course of daratumumab in patients with multiple myeloma and minimal residual disease after induction therapyKarthik Nath, Tala Shekarkhand, Meghan Salcedo, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 23, 2020
Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple MyelomaSusan Bal, Heather J Landau, Gunjan L Shah, et al.
Research Square|February 26, 2024
Comparison of Infectious Complications with BCMA-directed Therapies in Multiple MyelomaAlexander Lesokhin, Karthik Nath, Tala Shekarkhand, et al.
Leukemia & Lymphoma|December 23, 2015
Bone marrow abnormalities and early bone lesions in multiple myeloma and its precursor disease: a prospective study using functional and morphologic imagingManisha Bhutani, Baris Turkbey, Esther Tan, et al.
Pageof 18